Company says it will seek approval of Alzheimer’s drug
Tuesday, 22 October 2019 The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer’s disease. It’s a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday is a surprise because the company earlier this year stopped two studies of the drug when partial results suggested it was not working. Biogen says a new analysis of more results suggest it has some benefits at the highest dose. The drug company Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat...
Shares of Biogen skyrocketed roughly 40 percent Tuesday after the biotech company said it will seek approval for an Alzheimer's treatment after abandoning the drug earlier this year. Freddie Joyner has the story.
The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ:... bizjournals Also reported by •Proactive Investors